Thomson Reuters content is at the center of thousands of investment decisions, everyday. Our clients and partners span the full breadth of the investment community, from wealth and portfolio managers, to investment bankers and CEOs. Our content experts know our data inside and out. They are industry thought leaders and the power behind each new and exciting enhancement, including the recently launched Point in Time database for Fundamentals. Thomson Reuters continues to invest in innovation around our content assets to meet the growing needs of our customers. We are committed to providing the best data in the more useful ways to empower you to transform your thinking.

Steven Vestergaard, Chairman and CEO

Destiny Media Technologies Inc. - TSX.V: DSY - News Update

Abattis Biologix is a specialty biotechnology company engaged in the development, licensing, sale and distribution of botanical-based antiviral products. At present, the Company is focused on refining and bringing to market a proprietary nutraceutical formulation of botanical agents with demonstrated ability to inhibit the growth of, and reduce the severity and duration of various strains of human influenza and other viral diseases. Continuing research is being conducted at the Institute for Antiviral Research, Utah State University.

InvestmentPitch/Reuters - News Alert Video Program - Watch this video with Tara Sweder, and learn about this new and very cost-effective method of promoting your company to the global investment community.

InvestmentPitch.com - Video News Alert Program - Watch this video with Samantha Deutscher, and learn about this new and very cost-effective method of promoting your company to the global investment community.